ct041
carsgen therapeutics
['pancreatic', 'gastric', 'car t', 'ct041']
treatment with the claudin18.2 (cldn18.2) specific car t-cell therapy ct041 elicited either a response or stable disease in a majority of heavily pretreated patients with cldn18.2-positive advanced gastric and pancreatic adenocarcinoma #asco22 
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.